HUMDF Stock Chart & Stats
$0.58
$0.00(0.00%)
At close: 4:00 PM EDT
$0.58
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.25 - $0.62
Previous CloseN/A
Volume186.00K
Average Volume (3M)0.00
Market Cap
$312.06M
Enterprise Value$2.19K
Total Cash (Recent Filing)$1.09B
Total Debt (Recent Filing)$301.80M
Price to Earnings (P/E)1.9
Beta0.28
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.13
Shares Outstanding1,056,605,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.71
Price to Sales (P/S)5.69
P/FCF Ratio-45.79
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$132.67M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained double-digit top-line growth in 2025 signals strengthening product adoption and market penetration in the company’s core metabolic/diabetes market. Over a 2–6 month horizon this growth trend supports scale benefits, commercial traction and the potential to leverage R&D investment into higher recurring sales.
Improving Gross MarginA materially higher gross margin indicates improving unit economics and pricing or manufacturing efficiency. If maintained, this bolsters the company’s ability to fund operating investment and compress structural losses over time, offering a durable uplift to potential operating leverage as sales scale.
Stronger Balance Sheet PositionLower leverage and restored positive equity reduce solvency and refinancing risk, giving management flexibility to invest in commercialization and ongoing clinical programs. Stable total debt and an improved equity base provide a more durable financial runway versus the prior-year stressed position.
Bears Say
Negative Operating & Free Cash FlowPersistent negative operating and free cash flow reduces internal funding for R&D and commercialization and increases reliance on external financing. Over months this can pressure strategic flexibility, raise funding costs, and force trade-offs between growth investments and capital preservation.
Operating Losses Despite Revenue GrowthLarge negative operating and EBITDA margins show the company has not yet converted revenue momentum into sustainable profitability. If structural cost base or SG&A and R&D intensity remain high, continued operating losses will hinder durable margin improvement and constrain free cash flow generation.
Earnings Quality & Financial VolatilityA divergence between reported net income and cash flow, plus prior swings in equity, suggest earnings are influenced by non-operating items and volatility. This weakens confidence in repeatable profits, complicates forecasting, and increases the risk of future balance-sheet or funding stress over the medium term.
Hua Medicine News
HUMDF FAQ
What was Hua Medicine Ltd.’s price range in the past 12 months?
Hua Medicine Ltd. lowest stock price was $0.25 and its highest was $0.62 in the past 12 months.
What is Hua Medicine Ltd.’s market cap?
Hua Medicine Ltd.’s market cap is $312.06M.
When is Hua Medicine Ltd.’s upcoming earnings report date?
Hua Medicine Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 26 days.
How were Hua Medicine Ltd.’s earnings last quarter?
Hua Medicine Ltd. released its earnings results on Mar 26, 2026. The company reported -$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Hua Medicine Ltd. overvalued?
According to Wall Street analysts Hua Medicine Ltd.’s price is currently Overvalued.
Does Hua Medicine Ltd. pay dividends?
Hua Medicine Ltd. does not currently pay dividends.
What is Hua Medicine Ltd.’s EPS estimate?
Hua Medicine Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hua Medicine Ltd. have?
Hua Medicine Ltd. has 1,056,605,000 shares outstanding.
What happened to Hua Medicine Ltd.’s price movement after its last earnings report?
Hua Medicine Ltd. reported an EPS of -$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Hua Medicine Ltd.?
Currently, no hedge funds are holding shares in HUMDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hua Medicine Ltd.
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
Technical Analysis
HUTCHMED (China)
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
Ownership Overview
―
Insiders
<0.01% Other Institutional Investors
99.70% Public Companies and
Individual Investors